![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VBI Vaccines Lands Deal to Develop COVID-19 Vaccine in Canada
VBI Vaccines Lands Deal to Develop COVID-19 Vaccine in Canada
![VBIVaccinesLogo-430x250.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/VBIVaccinesLogo-430x250.png?t=1600727141&width=430)
September 22, 2020
Massachusetts-based VBI Vaccines has entered into an agreement with the Canadian government to develop a coronavirus vaccine through phase 2 testing by 2022.
Under the agreement, VBI subsidiary Variation Biotechnologies will develop a broadly reactive vaccine against COVID-19, Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome, or a vaccine targeting only COVID-19.
The government will contribute $42 million for the project and about 75 percent of VBI’s costs for the study, which is expected to be exclusively conducted in Canada.
Upcoming Events
-
21Oct